-$0.70 Earnings Per Share Expected for Arcadia Biosciences Inc (NASDAQ:RKDA) This Quarter

Share on StockTwits

Analysts expect Arcadia Biosciences Inc (NASDAQ:RKDA) to report earnings per share (EPS) of ($0.70) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Arcadia Biosciences’ earnings. The lowest EPS estimate is ($0.72) and the highest is ($0.68). Arcadia Biosciences posted earnings of ($0.14) per share in the same quarter last year, which indicates a negative year over year growth rate of 400%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 25th.

According to Zacks, analysts expect that Arcadia Biosciences will report full year earnings of ($3.16) per share for the current fiscal year, with EPS estimates ranging from ($3.17) to ($3.15). For the next year, analysts expect that the business will post earnings of ($2.19) per share, with EPS estimates ranging from ($2.54) to ($1.84). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Arcadia Biosciences.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27). The firm had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.

Several equities research analysts have recently commented on the company. ValuEngine downgraded Arcadia Biosciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating on shares of Arcadia Biosciences in a report on Monday, August 12th. Finally, National Securities upped their price target on Arcadia Biosciences from $12.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 15th.

In other Arcadia Biosciences news, Director Kevin Comcowich acquired 5,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $5.88 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at $117,600. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders acquired 32,200 shares of company stock worth $188,076. Insiders own 3.30% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in Arcadia Biosciences in the second quarter worth $32,000. Cambridge Investment Research Advisors Inc. purchased a new position in Arcadia Biosciences in the second quarter worth $34,000. Squarepoint Ops LLC purchased a new position in Arcadia Biosciences in the third quarter worth $124,000. Sabby Management LLC boosted its position in Arcadia Biosciences by 150.0% in the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Arcadia Biosciences by 47.1% in the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after purchasing an additional 37,472 shares during the last quarter. 8.03% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ RKDA traded up $0.22 during midday trading on Wednesday, hitting $5.19. 3,833 shares of the stock traded hands, compared to its average volume of 685,477. The company has a market cap of $42.99 million, a PE ratio of -0.97 and a beta of -2.98. Arcadia Biosciences has a one year low of $1.82 and a one year high of $10.40. The business has a 50 day moving average price of $4.69 and a two-hundred day moving average price of $4.68. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.27 and a current ratio of 5.58.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Recommended Story: Stock Portfolio Tracker

Get a free copy of the Zacks research report on Arcadia Biosciences (RKDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.